Genmab | GEN - Assets


Genmab reported DKK12.87B in Assets for its fiscal quarter ending in December of 2025.





Assets Change Date
Agios Pharmaceuticals USD 1.3B 88.48M Dec/2025
Almirall EUR 2.34B 29.21M Dec/2025
Amarin USD 670.78M 10.96M Dec/2025
Amgen USD 90.59B 445M Dec/2025
argenx SE USD 7.18B 973.07M Jun/2025
AstraZeneca USD 114.07B 382M Dec/2025
Bayer EUR 104.54B 331M Dec/2025
BioMarin Pharmaceutical USD 7.59B 20.85M Dec/2025
Demant DKK 39.07B 6.43B Dec/2025
Exelixis USD 2.84B 20.87M Dec/2025
Fresenius Medical Care EUR 31B 115.33M Dec/2025
Galapagos EUR 3.41B 105.39M Dec/2025
Genmab DKK 12.87B 5.85B Dec/2025
GlaxoSmithKline GBP 61.12B 221M Dec/2025
GN Store Nord DKK 29.23B 170M Dec/2025
GRIFOLS EUR 19.71B 141.77M Dec/2025
Hikma Pharmaceutical USD 5.67B 117M Dec/2025
Insmed USD 2.26B 96.18M Dec/2025
Lonza CHF 18.97B 164M Dec/2025
Merck EUR 51.53B 600M Dec/2025
Novartis USD 110.95B 3.66B Dec/2025
Regeneron Pharmaceuticals USD 40.56B 389.3M Dec/2025
Roche Holding CHF 100.7B 5.94B Dec/2025
Sanofi EUR 126.81B 2.99B Dec/2025
UCB EUR 18.16B 971M Dec/2025